Results from the UK-based Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) led an expert panel to issue a guideline recommendation against systematic screening, which also emphasised the need for shared decision-making between patients and clinicians.7,33. Here, KLK3 is linked to prostate carcinoma.